GlobeNewswire: Cure Pharmaceutical Holding Corp. Contains the last 10 of 95 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T01:13:56ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/09/02/2509125/0/en/Cure-Pharmaceutical-Reports-Second-Quarter-2022-Results-With-Increased-Sequential-Revenues-and-Strong-Margins.html?f=22&fvtc=4&fvtv=30917Cure Pharmaceutical Reports Second Quarter 2022 Results With Increased Sequential Revenues and Strong Margins2022-09-02T10:00:00Z<![CDATA[Balance Sheet and Governance Strengthened with Asset Sale and Board Appointments]]>https://www.globenewswire.com/news-release/2022/08/16/2498844/0/en/CURE-Pharmaceutical-Announces-Rob-Davidson-as-new-Chairman-of-the-Board-and-Appointment-of-Rob-Costantino-as-Member-of-the-Board-and-Audit-Committee-Chairman.html?f=22&fvtc=4&fvtv=30917CURE Pharmaceutical Announces Rob Davidson as new Chairman of the Board and Appointment of Rob Costantino as Member of the Board and Audit Committee Chairman2022-08-16T10:00:00Z<![CDATA[Rob Davidson brings a deep understanding of CURE pipeline, provides expertise in continued new product development, patent creation and continuity in non-dilutive on-going deal transactions and years of public company experience.]]>https://www.globenewswire.com/news-release/2022/08/09/2494939/0/en/CURE-Pharmaceutical-Provided-Full-Corporate-Update-on-Recent-Shareholder-Call.html?f=22&fvtc=4&fvtv=30917CURE Pharmaceutical Provided Full Corporate Update on Recent Shareholder Call2022-08-09T13:00:00Z<![CDATA[OXNARD, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company hosted a shareholder call on Wednesday, August 3, 2022. On the recorded call/webcast, the executive management team provided details on the recent $20 million non-dilutive sale of a portion of its product and intellectual property portfolio and provided a full business update.]]>https://www.globenewswire.com/news-release/2022/08/02/2490468/0/en/CURE-Pharmaceutical-Announces-the-Appointment-of-New-Board-Member.html?f=22&fvtc=4&fvtv=30917CURE Pharmaceutical Announces the Appointment of New Board Member2022-08-02T13:00:00Z<![CDATA[Gerald Bagg brings deep understanding of CPG to CURE Gerald Bagg brings deep understanding of CPG to CURE]]>https://www.globenewswire.com/news-release/2022/08/01/2489470/0/en/CURE-Pharmaceutical-Announces-Teleconference-With-Investors.html?f=22&fvtc=4&fvtv=30917CURE Pharmaceutical Announces Teleconference With Investors2022-08-01T13:00:00Z<![CDATA[Updates on Recent Transaction and Business will be Provided Updates on Recent Transaction and Business will be Provided]]>https://www.globenewswire.com/news-release/2022/07/28/2487946/0/en/CURE-Pharmaceutical-Announces-the-Sale-of-a-Portion-of-its-Platform-Technology-IP-for-20-Million.html?f=22&fvtc=4&fvtv=30917CURE Pharmaceutical Announces the Sale of a Portion of its Platform Technology IP for $20 Million2022-07-28T13:00:00Z<![CDATA[Proceeds Will Be Used to Grow CURE’s Wellness and Beauty Brands and Its Remaining Proprietary Platform Technology Proceeds Will Be Used to Grow CURE’s Wellness and Beauty Brands and Its Remaining Proprietary Platform Technology]]>https://www.globenewswire.com/news-release/2022/05/12/2442338/0/en/CURE-Pharmaceutical-Announces-Positive-Findings-from-Study-at-Cincinnati-Children-s-Hospital-Medical-Center-CCHMC-Using-CURE-s-Proprietary-Oral-Thin-Film-OTF-High-Single-Dose-Vitam.html?f=22&fvtc=4&fvtv=30917CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children’s Hospital Medical Center (CCHMC) Using CURE’s Proprietary, Oral Thin Film (OTF) High, Single Dose Vitamin D in Pediatric Patients Pre- and Post-Hematopoietic Stem Cell Transplantation (HSCT)2022-05-12T17:42:05Z<![CDATA[OXNARD, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holdings (OTC: CURR), a developer and manufacturer of innovative delivery formulations for drugs, supplements and wellness products, today announced positive finding from a study conducted at Cincinnati Children’s Hospital Medical Center (CCHMC) using CURE’s proprietary, single dose, oral, 40,000 IU vitamin D (branded ImmunD3™ Nutri-Strips™ in the retail wellness market) in pediatric patients before stem cell therapy. CURE’s oral Vitamin D supplement was found to be more effective than standard supplementation in achieving pre- and post-surgery vitamin D sufficiency, which is critical for reducing immune-mediated organ damage in the children receiving HSCT.]]>https://www.globenewswire.com/news-release/2022/04/14/2422696/0/en/Sera-Labs-Inc-Products-Now-Available-at-Walmart-Bed-Bath-Beyond-CVS-and-Target-com.html?f=22&fvtc=4&fvtv=30917Sera Labs Inc. Products Now Available at Walmart, Bed Bath & Beyond, CVS and Target.com2022-04-14T12:00:00Z<![CDATA[LOS ANGELES, April 14, 2022 (GLOBE NEWSWIRE) -- Sera Labs, a wholly subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced its Seratopical Revolution skincare line will be sold at select Walmart Stores, as well as CVS, and Bed Bath & Beyond stores. Sera Labs also has garnered placement for its revolutionary oral thin film strip, Nutri-Strips™ on shelves at CVS and at Target.com. The Nutri-Strip technology is proprietary to Sera Labs and is the result of years of research and more than 25 patents by CURE Pharmaceutical.]]>https://www.globenewswire.com/news-release/2022/03/03/2396551/0/en/CURE-Pharmaceutical-and-Milagro-Pharmaceuticals-Collaborate-for-Registration-and-Approval-to-Sell-Sildenafil-Oral-Thin-Film-in-Mexico.html?f=22&fvtc=4&fvtv=30917CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval to Sell Sildenafil Oral Thin Film in Mexico2022-03-03T16:18:13Z<![CDATA[COFEPRIS (Mexico’s equivalent of the US FDA) grants authorization for the manufacture, distribution and sale in Mexico of CURE’s Sildenafil, Vitamin D3, Electrolyte, Energy, and Sleep products in CURE’s patented Oral Thin Film (OTF) dose form CUREform™ COFEPRIS (Mexico’s equivalent of the US FDA) grants authorization for the manufacture, distribution and sale in Mexico of CURE’s Sildenafil, Vitamin D3, Electrolyte, Energy, and Sleep products in CURE’s patented Oral Thin Film (OTF) dose form CUREform™]]>https://www.globenewswire.com/news-release/2021/12/09/2349092/0/en/Sera-Labs-a-Subsidiary-of-CURE-Pharmaceutical-Consummates-Exclusive-International-Distribution-Agreement-With-Leading-Canadian-Distributor.html?f=22&fvtc=4&fvtv=30917Sera Labs, a Subsidiary of CURE Pharmaceutical, Consummates Exclusive International Distribution Agreement With Leading Canadian Distributor2021-12-09T12:30:00Z<![CDATA[Northern Response International To Distribute Seratopical Revolution® Masstige Line Northern Response International To Distribute Seratopical Revolution® Masstige Line]]>Seratopical Revolution marries nature and science into one clean and nourishing line of beauty products. The line’s P3P complex, developed by CURE Pharmaceutical, drives natural, clean, plant-based ingredients into the deeper layers of the skin by utilizing a proprietary tri-peptide delivery system. Unlike other companies that use alcohol as a delivery system, which is incredibly drying to the skin, Seratopical Revolution’s natural oil and surfactant delivery systems are highly efficacious and offer near immediate results.Seratopical Revolution Line